A
Alessandra Marrazzo
Researcher at University of Modena and Reggio Emilia
Publications - 7
Citations - 640
Alessandra Marrazzo is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Metabolic syndrome. The author has an hindex of 5, co-authored 6 publications receiving 446 citations. Previous affiliations of Alessandra Marrazzo include National Operating Committee on Standards for Athletic Equipment.
Papers
More filters
Journal ArticleDOI
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.
Stefano Ballestri,Fabio Nascimbeni,Enrica Baldelli,Alessandra Marrazzo,Dante Romagnoli,Amedeo Lonardo +5 more
TL;DR: Nonalcoholic fatty liver disease (NAFLD) spans steatosis through nonalcoholic steatohepatis, cirrhosis, and hepatocellular carcinoma associated with striking systemic features and excess cardiovascular and liver-related mortality.
Journal ArticleDOI
Nonalcoholic fatty liver disease: Evolving paradigms
Amedeo Lonardo,Fabio Nascimbeni,Mauro Maurantonio,Alessandra Marrazzo,Luca Rinaldi,Luigi Elio Adinolfi +5 more
TL;DR: NAFLD is highly prevalent in certain cohorts of individuals who are thus potentially amenable to selective screening strategies, intensive follow-up schedules for early identification of liver-related and extrahepatic complications and in whom earlier and more aggressive treatment schedules should be carried out whenever possible.
Journal ArticleDOI
Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases
Stefano Ballestri,Fabio Nascimbeni,Enrica Baldelli,Alessandra Marrazzo,Dante Romagnoli,Giovanni Targher,Amedeo Lonardo +6 more
TL;DR: US-FLI accurately identifies histological severity and is correlated with metabolic parameters in patients with various steatogenic liver diseases, and is an easy and versatile tool for the screening of steatosis and the metabolic health of these patients.
Journal ArticleDOI
Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.
Stefano Ballestri,Alessandro Mantovani,Enrica Baldelli,Simonetta Lugari,Mauro Maurantonio,Fabio Nascimbeni,Alessandra Marrazzo,Dante Romagnoli,Giovanni Targher,Amedeo Lonardo +9 more
TL;DR: In this article, the diagnostic performance of various liver fibrosis biomarkers for identifying histological significant/advanced fibrosis was compared with cardiovascular risk (CVR) scores in chronic liver disease patients.
Journal ArticleDOI
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma
TL;DR: It is demonstrated that sofosbuvir- based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy.